Results 91 to 100 of about 3,323,629 (269)
Demographic characteristics of prostate cancer patients according to use of androgen deprivation therapy, radiotherapy, and radical prostatectomy.
Yu-Li Su (761278) +5 more
core +1 more source
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki +6 more
wiley +1 more source
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. [PDF]
We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer.
Parmar, MK +54 more
core +1 more source
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal +4 more
wiley +1 more source
Where does fat regionally accumulate during androgen deprivation therapy?
Where does fat regionally accumulate during androgen deprivation ...
Trish Livingston (13098306) +6 more
core
Aim: Exercise for prostate cancer (PC) survivors has been shown to be effective in addressing metabolic function and associated comorbidities (eg, diabetes, cardiovascular disease, etc), as well as sarcopenia and significant functional impairment ...
Scuffham, Paul +14 more
core +1 more source
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary analysis of patient‐level data from the phase 3 SWOG 1216 randomized clinical trial to evaluate whether TTM is ...
Nicolas Sayegh +15 more
wiley +1 more source
Radiation therapy is often combined with androgen deprivation therapy in the treatment of aggressive localized prostate cancer. However, castration-resistant disease may not respond to testosterone deprivation approaches.
Konjeti R Sekhar +3 more
doaj +1 more source
Cardiovascular risk with androgen deprivation therapy
From the primary care perspective, many urologists and oncologists appear to be ignoring an FDA warning to assess patients' cardiovascular (CV) risk before instituting androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists.
openaire +2 more sources
Does Androgen Deprivation Therapy Impact Subjective Cognitive Function in Men with Non-metastatic Prostate Cancer? [PDF]
Androgen-deprivation therapy is used to treat almost 50% of current prostate cancer patients. Despite slowing disease progression and prolonging survival, androgen-deprivation therapy is associated with numerous side effects.
Marzouk, Shireen
core +1 more source

